Search Within

Joachim Yahalom

  1. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (123)
  2. Journal Article (100)
  3. Book Section (17)
  4. Research Letter (4)
  5. Conference Paper (3)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (248)
  2. Radiation Oncology, Department of (248)
  3. Survivorship Research (248)
  4. Department of Medicine (243)
  5. Hematologic Malignancies, Division of (243)
  6. Lymphoma (205)

More Groups

People
  1. Andrew Zelenetz (116)
  2. David Straus (82)
  3. Ariela Noy (71)
  4. Craig Moskowitz (71)
  5. Steven Horwitz (65)
  6. Maria Palomba (63)

More People

Years
  1. 2025 (3)
  2. 2024 (17)
  3. 2023 (28)
  4. 2022 (11)
  5. 2021 (13)
  6. 2020 (12)

More Years

Publications
  1. Blood (77)
  2. International Journal of Radiation Oncology, Biology, Physics (25)
  3. Hematological Oncology (20)
  4. Journal of Clinical Oncology (16)
  5. Journal of the National Comprehensive Cancer Network (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (85)
  2. Elsevier Inc. (40)
  3. Wiley Blackwell (23)
  4. American Society of Clinical Oncology (16)
  5. Harborside Press (14)
  6. Nature Publishing Group (12)

More Publishers

Results (248)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
    Journal Article

    Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy
    Journal Article

    Imber, B. S.; Sadelain, M.; DeSelm, C.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Giralt, S.; Park, J. H.; Sauter, C.; Scordo, M.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Rosai-Dorfman disease - Utility of (18)F-FDG PET/CT for initial evaluation and follow-up
    Journal Article

    Mahajan, S.; Nakajima, R.; Yabe, M.; Dogan, A.; Ulaner, G. A.; Yahalom, J.; Noy, A.; Diamond, E. L.; Schòˆder, H.
    Clinical Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Highly favorable outcomes with salvage radiation therapy followed by autologous transplant in relapsed and refractory DLBCL patients with minimal or no response to salvage chemotherapy
    Meeting Abstract

    Yang, J. C.; Chau, K.; Scordo, M.; Sauter, C. S.; Yahalom, J.
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Early experience using radiotherapy as a salvage treatment for relapsed or refractory non-Hodgkin lymphomas following CD19 chimeric antigen receptor modified T-cell therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Dahi, P. B.; Sauter, C. S.; Scordo, M.; Batlevi, C. L.; Park, J. H.; Shah, G. L.; Giralt, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Batlevi, C. L.; Dahi, P. B.; Giralt, S. A.; Noy, A.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save